In November 2025, the Ministry of Health approved new Agreements concerning the designation of Benchmark centers, departments, and units of the National Health System (CSURs) for the treatment of rare or complex pathologies. These updates include the decision on new procedures requiring CSUR designation (surgery for complex central airway stenosis), as well as the designation, redesignation, and revocation of CSURs across multiple fields, including in the endocrine, endoscopy, gastrointestinal, nephrology and urology, neurology and neurosurgery, neuromodulation, and neurovascular fields.

In late November – early December 2025, the application period for 2027 OPS (procedure codes) and DRG changes was opened by the Federal Institute for Drugs and Medical Devices (BfArM) and the Institute for Hospital Remuneration Systems (INeK), respectively.

On November 28, 2025, the entity managing the DRG system in Switzerland, SwissDRG, published the final (billing) version of the 2026 DRG system. In total, 19 new DRGs related to cardiovascular, ENT, gastrointestinal, neurology and neurosurgery, obstetrics and gynecology, orthopedics, and some other fields were introduced. Also, four new add-on reimbursement categories were added.

In November 2025, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned procalcitonin evaluation of antibiotic use in COVID-19 hospitalized patients, comparison of the knee arthroplasty versus joint distraction for osteoarthritis, comparison of surgical approaches for mitral valve repair, as well as comparison of sample types for diagnostics of infected diabetic foot ulcers.

In November 2025, the annual update of the Swedish NordDRG system was published to come into force on January 1, 2026. Five new DRGs were introduced. In 2026, to obtain DRG tariffs, individual DRG cost weights must be multiplied by a base rate of 81,142 SEK.

On November 23, 2025, the Norwegian Directorate of Health released an updated version (v.78) of the Norwegian Laboratory Code (NLK) system, along with associated tariffs, for both state and private laboratories. A total of 42 new codes were added in the biochemistry, microbiology, clinical pharmacology, and immunology fields.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Severens et al. analyzed Europe-wide perspectives on the implementation of the EU HTA Regulation, mapping key implementation challenges and proposing actions to support a smoother transition.

In November 2025, the HTA body of Tuscany Regional Healthcare published six rapid HTA reports (five new assessments and one reassessment) on medical devices in the cardiovascular, gastroenterology, ophthalmology, dermatology and surgical fields.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of December 1st, we plan to work on 23 projects. Review the complete list of planned activities in this post.

In November 2025, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedures Guidance on low-energy contact X-ray brachytherapy for rectal cancer with different recommendations depending on clinical indications. Furthermore, three new clinical guidelines were released.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, De Cassai et al. presented a comprehensive methodological guide outlining how to design, conduct, and report high-quality systematic reviews across biological and health sciences.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the November 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). One favourable opinion was issued concerning add-on reimbursement for medical device in the gastrointestinal field.